Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 21;110(Supplement_1):S25-S36.
doi: 10.1210/clinem/dgae718.

Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

Affiliations
Review

Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

Hedi L Claahsen-van der Grinten et al. J Clin Endocrinol Metab. .

Abstract

Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency results in severe cortisol and aldosterone deficiency, leading to persistent adrenal stimulation and excess production of ACTH and adrenal androgens. This review examines the clinical considerations and challenges of balancing under- and overtreatment with glucocorticoids in adolescent and adult male individuals with CAH. Adolescents face many unique challenges that can hinder adherence, hormonal control, and transition to independence. Thus, patient education is critical during adolescence, especially in poorly controlled postpubertal males who lack obvious symptoms and may not recognize the long-term consequences of nonadherence, such as reduced final height, reduced reproductive health, poor bone health, obesity, and hypertension. The risk of subfertility/infertility begins early, especially in males with poor hormonal control, who often have reduced sperm counts, small testes, and benign tumors called testicular adrenal rest tumors (TARTs). Even males with good hormonal control can experience subfertility/infertility due to TARTs. In addition, several factors such as hypogonadism and long-term glucocorticoid treatment can predispose males with CAH to poor bone health (eg, low bone mineral density, increased risk of osteoporosis/osteopenia and fractures) and metabolic syndrome (eg, obesity, insulin resistance, dyslipidemia, and hypertension). Regular monitoring is recommended, with glucocorticoid dose optimization and prophylactic treatment to maximize future fertility potential and protect long-term bone health. Early implementation of lifestyle interventions and medical treatment are needed to address cardiometabolic consequences.

Keywords: bone health; cardiometabolic health; congenital adrenal hyperplasia; hypergonadotropic hypogonadism; testicular adrenal rest tumors; transition of care.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overview of pubertal changes and clinical considerations in adolescent and adult males with classic CAH. Abbreviations: BMD, bone mineral density; CAH, congenital adrenal hyperplasia; TARTs, testicular adrenal rest tumors.
Figure 2.
Figure 2.
Male gonadal dysfunction in CAH: overview (A) and treatment options (B). aIntensifying GC treatment should always be the first option. Other treatment options can be considered for specific situations. bTo facilitate assisted reproductive techniques. Adapted with permission from Sarafoglou 2023 J Clin Endocrinol Metabol. Abbreviations: ACTH, adrenocorticotropic hormone; CAH, congenital adrenal hyperplasia; FSH, follicle-stimulating hormone; hCG, human chorionic gonadotropin; LH, luteinizing hormone; TART, testicular adrenal rest tumor.

Similar articles

Cited by

References

    1. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043‐4088. - PMC - PubMed
    1. Merke DP, Auchus RJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 2020;383(13):1248‐1261. - PubMed
    1. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev. 2022;43(1):91‐159. - PMC - PubMed
    1. van der Straaten S, Springer A, Zecic A, et al. The External Genitalia Score (EGS): a European multicenter validation study. J Clin Endocrinol Metab. 2020;105(3):e222‐e230. - PubMed
    1. Whittle E, Falhammar H. Glucocorticoid regimens in the treatment of congenital adrenal hyperplasia: a systematic review and meta-analysis. J Endocr Soc. 2019;3(6):1227‐1245. - PMC - PubMed

Substances

Supplementary concepts